| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 26 | 2023 | 1869 | 2.310 |
Why?
|
| Global Health | 12 | 2020 | 555 | 2.280 |
Why?
|
| Pediatrics | 16 | 2020 | 1158 | 2.010 |
Why?
|
| Acquired Immunodeficiency Syndrome | 5 | 2023 | 232 | 1.830 |
Why?
|
| Pneumococcal Infections | 18 | 2007 | 274 | 1.440 |
Why?
|
| Preceptorship | 3 | 2019 | 33 | 1.340 |
Why?
|
| Anti-HIV Agents | 7 | 2018 | 308 | 1.210 |
Why?
|
| Attitude of Health Personnel | 4 | 2019 | 669 | 1.170 |
Why?
|
| Streptococcus pneumoniae | 23 | 2011 | 372 | 0.960 |
Why?
|
| Ehrlichiosis | 5 | 2007 | 10 | 0.880 |
Why?
|
| International Cooperation | 3 | 2017 | 157 | 0.760 |
Why?
|
| Infant | 68 | 2018 | 12454 | 0.730 |
Why?
|
| Child | 74 | 2023 | 24466 | 0.720 |
Why?
|
| Salmonella Infections | 6 | 2004 | 32 | 0.710 |
Why?
|
| Health Resources | 4 | 2019 | 115 | 0.710 |
Why?
|
| Child, Preschool | 63 | 2019 | 14043 | 0.700 |
Why?
|
| Meningitis, Bacterial | 6 | 2011 | 94 | 0.670 |
Why?
|
| Sarcoma, Kaposi | 6 | 2019 | 120 | 0.660 |
Why?
|
| Salmonella | 7 | 2004 | 28 | 0.650 |
Why?
|
| Anti-Bacterial Agents | 25 | 2016 | 2411 | 0.650 |
Why?
|
| International Educational Exchange | 1 | 2019 | 17 | 0.640 |
Why?
|
| Organizational Innovation | 1 | 2018 | 44 | 0.610 |
Why?
|
| AIDS-Related Opportunistic Infections | 2 | 2013 | 136 | 0.590 |
Why?
|
| Haemophilus influenzae | 5 | 2011 | 130 | 0.580 |
Why?
|
| Problem-Based Learning | 1 | 2018 | 72 | 0.580 |
Why?
|
| Bacteremia | 9 | 2015 | 406 | 0.580 |
Why?
|
| Professionalism | 1 | 2018 | 47 | 0.580 |
Why?
|
| Humans | 131 | 2023 | 124231 | 0.560 |
Why?
|
| Perception | 1 | 2018 | 220 | 0.550 |
Why?
|
| Time-to-Treatment | 1 | 2018 | 188 | 0.540 |
Why?
|
| Tuberculosis | 2 | 2020 | 517 | 0.530 |
Why?
|
| Pneumococcal Vaccines | 5 | 2005 | 168 | 0.530 |
Why?
|
| Students, Medical | 2 | 2018 | 356 | 0.530 |
Why?
|
| Internship and Residency | 6 | 2020 | 1170 | 0.520 |
Why?
|
| Curriculum | 6 | 2020 | 723 | 0.520 |
Why?
|
| Developing Countries | 2 | 2017 | 268 | 0.520 |
Why?
|
| Arkansas | 16 | 2004 | 58 | 0.490 |
Why?
|
| Haemophilus Infections | 3 | 2003 | 91 | 0.460 |
Why?
|
| Male | 71 | 2020 | 60871 | 0.460 |
Why?
|
| HIV | 2 | 2012 | 180 | 0.460 |
Why?
|
| Zika Virus | 1 | 2016 | 142 | 0.460 |
Why?
|
| Female | 76 | 2020 | 66254 | 0.460 |
Why?
|
| Zika Virus Infection | 1 | 2016 | 169 | 0.440 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2013 | 52 | 0.430 |
Why?
|
| Cross Infection | 4 | 2004 | 331 | 0.420 |
Why?
|
| Delivery of Health Care | 1 | 2018 | 605 | 0.410 |
Why?
|
| Health Personnel | 3 | 2017 | 504 | 0.410 |
Why?
|
| Malawi | 11 | 2019 | 394 | 0.410 |
Why?
|
| Polymerase Chain Reaction | 6 | 2012 | 1583 | 0.410 |
Why?
|
| Adolescent | 36 | 2020 | 19300 | 0.400 |
Why?
|
| Tanzania | 4 | 2020 | 66 | 0.400 |
Why?
|
| Hepatitis B virus | 1 | 2013 | 136 | 0.400 |
Why?
|
| HIV Antibodies | 1 | 2012 | 69 | 0.400 |
Why?
|
| Cephalosporins | 9 | 2002 | 138 | 0.390 |
Why?
|
| Academies and Institutes | 1 | 2012 | 83 | 0.390 |
Why?
|
| Hepatitis B | 1 | 2013 | 160 | 0.390 |
Why?
|
| Antiretroviral Therapy, Highly Active | 5 | 2016 | 266 | 0.390 |
Why?
|
| Microbial Sensitivity Tests | 14 | 2011 | 783 | 0.380 |
Why?
|
| HIV Seropositivity | 1 | 2012 | 117 | 0.380 |
Why?
|
| Coinfection | 1 | 2013 | 171 | 0.370 |
Why?
|
| Meningitis, Cryptococcal | 1 | 2011 | 21 | 0.370 |
Why?
|
| Rocky Mountain Spotted Fever | 3 | 2007 | 7 | 0.370 |
Why?
|
| DNA, Viral | 1 | 2012 | 481 | 0.360 |
Why?
|
| Retrospective Studies | 33 | 2019 | 16208 | 0.360 |
Why?
|
| Africa South of the Sahara | 4 | 2020 | 118 | 0.360 |
Why?
|
| Physicians | 3 | 2016 | 583 | 0.360 |
Why?
|
| Penicillin Resistance | 7 | 2005 | 80 | 0.360 |
Why?
|
| Teaching | 3 | 2019 | 185 | 0.350 |
Why?
|
| DNA Fingerprinting | 5 | 2007 | 107 | 0.350 |
Why?
|
| Infant, Newborn | 28 | 2012 | 8172 | 0.340 |
Why?
|
| Drug Resistance, Microbial | 9 | 2016 | 192 | 0.340 |
Why?
|
| Clostridium Infections | 1 | 2012 | 245 | 0.320 |
Why?
|
| Serotyping | 14 | 2007 | 178 | 0.320 |
Why?
|
| Lesotho | 4 | 2019 | 17 | 0.310 |
Why?
|
| Ehrlichia chaffeensis | 4 | 2006 | 5 | 0.300 |
Why?
|
| Streptococcal Infections | 5 | 2015 | 244 | 0.300 |
Why?
|
| Focus Groups | 2 | 2019 | 202 | 0.290 |
Why?
|
| Meningococcal Vaccines | 2 | 2004 | 30 | 0.290 |
Why?
|
| Adult | 23 | 2020 | 29350 | 0.290 |
Why?
|
| Education, Medical, Continuing | 1 | 2008 | 138 | 0.280 |
Why?
|
| Meningococcal Infections | 2 | 2006 | 19 | 0.270 |
Why?
|
| Medication Adherence | 1 | 2010 | 392 | 0.260 |
Why?
|
| Malaria | 1 | 2006 | 83 | 0.260 |
Why?
|
| Ambulatory Care Facilities | 2 | 2018 | 229 | 0.250 |
Why?
|
| Africa | 4 | 2016 | 130 | 0.250 |
Why?
|
| Neisseria meningitidis | 3 | 2006 | 19 | 0.250 |
Why?
|
| Cooperative Behavior | 2 | 2017 | 220 | 0.240 |
Why?
|
| Blastomycosis | 2 | 1996 | 7 | 0.230 |
Why?
|
| Schools, Medical | 2 | 2017 | 111 | 0.230 |
Why?
|
| Viral Load | 2 | 2018 | 381 | 0.230 |
Why?
|
| Health Facility Closure | 1 | 2004 | 8 | 0.230 |
Why?
|
| Bacterial Infections | 3 | 2016 | 306 | 0.220 |
Why?
|
| Health Services Accessibility | 3 | 2018 | 604 | 0.220 |
Why?
|
| Faculty, Medical | 2 | 2020 | 262 | 0.220 |
Why?
|
| Cephalosporin Resistance | 5 | 2001 | 17 | 0.220 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 7 | 2007 | 92 | 0.210 |
Why?
|
| Anti-Retroviral Agents | 2 | 2016 | 137 | 0.210 |
Why?
|
| Career Mobility | 2 | 2020 | 50 | 0.210 |
Why?
|
| Pseudomonas Infections | 1 | 2004 | 116 | 0.210 |
Why?
|
| Fellowships and Scholarships | 2 | 2016 | 274 | 0.200 |
Why?
|
| Referral and Consultation | 1 | 2006 | 539 | 0.200 |
Why?
|
| Herpesvirus 8, Human | 2 | 2019 | 49 | 0.200 |
Why?
|
| Infection Control | 1 | 2004 | 160 | 0.200 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2004 | 166 | 0.200 |
Why?
|
| Malnutrition | 4 | 2014 | 200 | 0.200 |
Why?
|
| Cat-Scratch Disease | 3 | 2000 | 33 | 0.200 |
Why?
|
| Incidence | 12 | 2007 | 3077 | 0.190 |
Why?
|
| Doxycycline | 4 | 2007 | 115 | 0.190 |
Why?
|
| Splenectomy | 1 | 2002 | 64 | 0.190 |
Why?
|
| Seroepidemiologic Studies | 4 | 2013 | 121 | 0.190 |
Why?
|
| Infectious Disease Transmission, Vertical | 2 | 2012 | 240 | 0.190 |
Why?
|
| Salmonella Food Poisoning | 2 | 1998 | 3 | 0.190 |
Why?
|
| Spleen | 1 | 2002 | 280 | 0.180 |
Why?
|
| Specialization | 2 | 2015 | 76 | 0.180 |
Why?
|
| Bartonella Infections | 1 | 2000 | 7 | 0.180 |
Why?
|
| Tularemia | 2 | 1998 | 13 | 0.180 |
Why?
|
| Bartonella henselae | 1 | 2000 | 20 | 0.180 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2004 | 318 | 0.180 |
Why?
|
| Sepsis | 3 | 2011 | 478 | 0.180 |
Why?
|
| Whooping Cough | 2 | 2004 | 58 | 0.180 |
Why?
|
| Education, Medical, Graduate | 2 | 2015 | 511 | 0.180 |
Why?
|
| Catheterization, Central Venous | 1 | 2002 | 133 | 0.170 |
Why?
|
| Ceftriaxone | 7 | 2007 | 68 | 0.170 |
Why?
|
| Program Evaluation | 3 | 2018 | 448 | 0.170 |
Why?
|
| Education, Medical | 2 | 2017 | 289 | 0.170 |
Why?
|
| Patient Admission | 3 | 1998 | 185 | 0.170 |
Why?
|
| Alanine Transaminase | 2 | 2013 | 152 | 0.170 |
Why?
|
| Hospitalization | 6 | 2013 | 1752 | 0.170 |
Why?
|
| Clinical Competence | 2 | 2018 | 991 | 0.170 |
Why?
|
| Interleukin-6 | 2 | 2019 | 414 | 0.170 |
Why?
|
| Administrative Personnel | 1 | 2020 | 24 | 0.170 |
Why?
|
| Citrobacter | 1 | 1999 | 21 | 0.170 |
Why?
|
| Risk Factors | 15 | 2013 | 10118 | 0.170 |
Why?
|
| Poultry | 2 | 1996 | 6 | 0.170 |
Why?
|
| Mentoring | 1 | 2020 | 75 | 0.160 |
Why?
|
| Enterobacteriaceae Infections | 1 | 1999 | 55 | 0.160 |
Why?
|
| Drug Utilization | 2 | 2016 | 161 | 0.160 |
Why?
|
| Environmental Microbiology | 1 | 1999 | 16 | 0.160 |
Why?
|
| Efficiency, Organizational | 1 | 2019 | 56 | 0.160 |
Why?
|
| Organ Transplantation | 1 | 2001 | 164 | 0.160 |
Why?
|
| Program Development | 1 | 2020 | 187 | 0.160 |
Why?
|
| CD4 Lymphocyte Count | 3 | 2013 | 230 | 0.150 |
Why?
|
| Salmonella typhimurium | 3 | 2006 | 43 | 0.150 |
Why?
|
| Population Surveillance | 5 | 2006 | 389 | 0.150 |
Why?
|
| Models, Organizational | 1 | 2018 | 40 | 0.150 |
Why?
|
| Botswana | 3 | 2016 | 76 | 0.150 |
Why?
|
| Bone Marrow Transplantation | 1 | 2001 | 577 | 0.150 |
Why?
|
| Qualitative Research | 2 | 2019 | 543 | 0.150 |
Why?
|
| Reference Standards | 2 | 2018 | 240 | 0.150 |
Why?
|
| Drug Administration Schedule | 4 | 2012 | 725 | 0.150 |
Why?
|
| Antibodies, Bacterial | 4 | 2003 | 386 | 0.150 |
Why?
|
| Pneumonia | 2 | 2011 | 326 | 0.150 |
Why?
|
| Drug Resistance, Multiple | 1 | 1997 | 49 | 0.150 |
Why?
|
| Respiratory Syncytial Virus Infections | 2 | 1998 | 339 | 0.150 |
Why?
|
| Immunization, Passive | 1 | 1998 | 119 | 0.140 |
Why?
|
| Internationality | 1 | 2018 | 129 | 0.140 |
Why?
|
| Fever of Unknown Origin | 1 | 1998 | 45 | 0.140 |
Why?
|
| Canada | 1 | 2018 | 294 | 0.140 |
Why?
|
| Bibliometrics | 1 | 2017 | 29 | 0.140 |
Why?
|
| United States | 13 | 2018 | 10754 | 0.140 |
Why?
|
| Herpesviridae Infections | 1 | 2018 | 143 | 0.140 |
Why?
|
| Authorship | 1 | 2017 | 29 | 0.140 |
Why?
|
| Ceftizoxime | 1 | 1997 | 2 | 0.140 |
Why?
|
| Immunocompromised Host | 3 | 2007 | 295 | 0.140 |
Why?
|
| Hospitals, Pediatric | 4 | 2013 | 783 | 0.140 |
Why?
|
| Community Health Services | 1 | 2017 | 89 | 0.140 |
Why?
|
| Egg Shell | 1 | 1996 | 4 | 0.140 |
Why?
|
| Salmonella enteritidis | 1 | 1996 | 6 | 0.140 |
Why?
|
| Learning | 2 | 2018 | 363 | 0.140 |
Why?
|
| Quality Assurance, Health Care | 1 | 2018 | 209 | 0.130 |
Why?
|
| Eggs | 1 | 1996 | 24 | 0.130 |
Why?
|
| AIDS Serodiagnosis | 2 | 2013 | 56 | 0.130 |
Why?
|
| Epiglottitis | 1 | 1996 | 12 | 0.130 |
Why?
|
| Blastomyces | 1 | 1996 | 3 | 0.130 |
Why?
|
| Fever | 2 | 2000 | 296 | 0.130 |
Why?
|
| Learning Curve | 1 | 2016 | 53 | 0.130 |
Why?
|
| Lost to Follow-Up | 1 | 2016 | 32 | 0.130 |
Why?
|
| Foot Diseases | 1 | 1996 | 24 | 0.130 |
Why?
|
| Fluoroquinolones | 1 | 2016 | 92 | 0.130 |
Why?
|
| Macrolides | 2 | 2006 | 28 | 0.130 |
Why?
|
| Research | 1 | 2017 | 263 | 0.130 |
Why?
|
| Pharynx | 2 | 2006 | 64 | 0.130 |
Why?
|
| Staff Development | 2 | 2017 | 45 | 0.130 |
Why?
|
| Lice Infestations | 1 | 2015 | 1 | 0.120 |
Why?
|
| Pediculus | 1 | 2015 | 1 | 0.120 |
Why?
|
| Publishing | 1 | 2017 | 110 | 0.120 |
Why?
|
| Medication Errors | 1 | 2017 | 184 | 0.120 |
Why?
|
| Rickettsia rickettsii | 2 | 2007 | 3 | 0.120 |
Why?
|
| Pediatric Emergency Medicine | 1 | 2016 | 49 | 0.120 |
Why?
|
| Drug Resistance, Bacterial | 4 | 2006 | 363 | 0.120 |
Why?
|
| Urinary Tract Infections | 1 | 1999 | 299 | 0.120 |
Why?
|
| Streptococcus pyogenes | 2 | 2006 | 77 | 0.120 |
Why?
|
| Prospective Studies | 10 | 2019 | 6086 | 0.120 |
Why?
|
| Extracorporeal Circulation | 1 | 1995 | 53 | 0.120 |
Why?
|
| Neuromuscular Diseases | 1 | 1995 | 56 | 0.120 |
Why?
|
| Antitubercular Agents | 2 | 2014 | 247 | 0.120 |
Why?
|
| Heart Transplantation | 1 | 2001 | 858 | 0.120 |
Why?
|
| Professional Competence | 2 | 2015 | 97 | 0.120 |
Why?
|
| Buruli Ulcer | 1 | 2014 | 2 | 0.110 |
Why?
|
| Endocarditis | 1 | 2015 | 105 | 0.110 |
Why?
|
| Emergency Medicine | 1 | 2016 | 154 | 0.110 |
Why?
|
| Young Adult | 4 | 2018 | 8948 | 0.110 |
Why?
|
| Pneumonia, Pneumococcal | 4 | 2007 | 82 | 0.110 |
Why?
|
| False Negative Reactions | 2 | 2012 | 90 | 0.110 |
Why?
|
| Stevens-Johnson Syndrome | 1 | 2013 | 14 | 0.110 |
Why?
|
| Medical Records | 2 | 2007 | 190 | 0.110 |
Why?
|
| Cytokines | 1 | 2019 | 1272 | 0.110 |
Why?
|
| Sexually Transmitted Diseases | 1 | 1994 | 93 | 0.110 |
Why?
|
| Interdisciplinary Communication | 1 | 2014 | 134 | 0.110 |
Why?
|
| Antidiarrheals | 1 | 2013 | 17 | 0.110 |
Why?
|
| Salicylates | 1 | 2013 | 53 | 0.110 |
Why?
|
| Primary Prevention | 1 | 1994 | 166 | 0.110 |
Why?
|
| Syringes | 1 | 2013 | 24 | 0.110 |
Why?
|
| Hand Disinfection | 1 | 2012 | 16 | 0.100 |
Why?
|
| Pilot Projects | 3 | 2018 | 1396 | 0.100 |
Why?
|
| Cross-Sectional Studies | 4 | 2015 | 3410 | 0.100 |
Why?
|
| Cerebrospinal Fluid | 2 | 2011 | 95 | 0.100 |
Why?
|
| Bismuth | 1 | 2013 | 79 | 0.100 |
Why?
|
| Face | 1 | 2014 | 180 | 0.100 |
Why?
|
| Organometallic Compounds | 1 | 2013 | 108 | 0.100 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2012 | 53 | 0.100 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2012 | 66 | 0.100 |
Why?
|
| Penicillins | 5 | 2007 | 154 | 0.100 |
Why?
|
| Arachnid Vectors | 2 | 2006 | 10 | 0.100 |
Why?
|
| Antigens, Bacterial | 1 | 1994 | 311 | 0.100 |
Why?
|
| Meningitis, Pneumococcal | 3 | 1998 | 41 | 0.100 |
Why?
|
| Mycobacterium Infections | 2 | 2005 | 31 | 0.100 |
Why?
|
| Food Microbiology | 4 | 2002 | 25 | 0.100 |
Why?
|
| Histoplasmosis | 1 | 1992 | 45 | 0.100 |
Why?
|
| Lung Diseases | 1 | 1996 | 383 | 0.100 |
Why?
|
| Prevalence | 3 | 2013 | 2427 | 0.100 |
Why?
|
| Ticks | 2 | 2006 | 30 | 0.100 |
Why?
|
| Time Factors | 4 | 2016 | 6252 | 0.100 |
Why?
|
| Tuberculin Test | 1 | 1993 | 125 | 0.100 |
Why?
|
| Southeastern United States | 3 | 2007 | 37 | 0.100 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2016 | 418 | 0.100 |
Why?
|
| Opportunistic Infections | 1 | 1992 | 78 | 0.100 |
Why?
|
| Opsonin Proteins | 1 | 1991 | 21 | 0.100 |
Why?
|
| Cryptococcus | 1 | 2011 | 3 | 0.100 |
Why?
|
| Phagocytosis | 2 | 1994 | 169 | 0.100 |
Why?
|
| Hospitals | 2 | 2011 | 395 | 0.090 |
Why?
|
| Receptors, Complement | 1 | 1991 | 31 | 0.090 |
Why?
|
| Vaccines, Conjugate | 3 | 2005 | 78 | 0.090 |
Why?
|
| Staphylococcus epidermidis | 1 | 1991 | 41 | 0.090 |
Why?
|
| Role | 1 | 2011 | 26 | 0.090 |
Why?
|
| Ambulatory Care | 2 | 2013 | 378 | 0.090 |
Why?
|
| Diet | 1 | 1998 | 1133 | 0.090 |
Why?
|
| Medicine | 2 | 2016 | 97 | 0.090 |
Why?
|
| Follow-Up Studies | 6 | 2007 | 5094 | 0.090 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 1993 | 216 | 0.090 |
Why?
|
| Biomedical Research | 1 | 2017 | 519 | 0.090 |
Why?
|
| Social Responsibility | 1 | 2011 | 79 | 0.090 |
Why?
|
| Sensitivity and Specificity | 4 | 2004 | 2040 | 0.090 |
Why?
|
| Health Policy | 1 | 2012 | 211 | 0.090 |
Why?
|
| Ammonia | 1 | 1990 | 74 | 0.090 |
Why?
|
| Mass Screening | 2 | 2013 | 786 | 0.090 |
Why?
|
| Neutrophils | 2 | 1998 | 378 | 0.090 |
Why?
|
| Herpes Simplex | 1 | 1990 | 56 | 0.090 |
Why?
|
| Cefotaxime | 4 | 2001 | 35 | 0.090 |
Why?
|
| Caregivers | 2 | 2016 | 578 | 0.080 |
Why?
|
| Administration, Oral | 3 | 2016 | 676 | 0.080 |
Why?
|
| Communicable Disease Control | 1 | 2011 | 139 | 0.080 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2003 | 446 | 0.080 |
Why?
|
| Leprostatic Agents | 1 | 2009 | 2 | 0.080 |
Why?
|
| Leprosy | 1 | 2009 | 19 | 0.080 |
Why?
|
| Adoption | 1 | 2009 | 16 | 0.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 1237 | 0.080 |
Why?
|
| Recurrence | 4 | 2007 | 1423 | 0.080 |
Why?
|
| Inpatients | 1 | 2013 | 495 | 0.080 |
Why?
|
| Treatment Outcome | 13 | 2016 | 12260 | 0.070 |
Why?
|
| Heptavalent Pneumococcal Conjugate Vaccine | 2 | 2004 | 25 | 0.070 |
Why?
|
| Chi-Square Distribution | 2 | 2001 | 586 | 0.070 |
Why?
|
| Surveys and Questionnaires | 2 | 2015 | 3710 | 0.070 |
Why?
|
| Otitis Media | 2 | 2005 | 82 | 0.070 |
Why?
|
| Prognosis | 4 | 2016 | 4547 | 0.070 |
Why?
|
| Hypoalbuminemia | 1 | 2007 | 18 | 0.070 |
Why?
|
| Pregnancy Complications | 1 | 2012 | 506 | 0.070 |
Why?
|
| Molecular Epidemiology | 2 | 2006 | 155 | 0.070 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2011 | 373 | 0.070 |
Why?
|
| Aspartate Aminotransferases | 1 | 2007 | 79 | 0.070 |
Why?
|
| Lymphopenia | 1 | 2007 | 36 | 0.070 |
Why?
|
| Leukopenia | 1 | 2007 | 44 | 0.070 |
Why?
|
| Plasmodium | 1 | 2006 | 7 | 0.070 |
Why?
|
| Severity of Illness Index | 4 | 2016 | 2884 | 0.070 |
Why?
|
| Minisatellite Repeats | 1 | 2006 | 43 | 0.070 |
Why?
|
| Geography | 1 | 2006 | 110 | 0.070 |
Why?
|
| Antimalarials | 1 | 2006 | 38 | 0.070 |
Why?
|
| Demography | 1 | 2007 | 239 | 0.070 |
Why?
|
| Middle Aged | 4 | 2013 | 26363 | 0.070 |
Why?
|
| Gentamicins | 2 | 1998 | 95 | 0.070 |
Why?
|
| Hyponatremia | 1 | 2007 | 72 | 0.070 |
Why?
|
| Genotype | 4 | 2007 | 2548 | 0.070 |
Why?
|
| Anaplasma phagocytophilum | 1 | 2006 | 2 | 0.070 |
Why?
|
| Animals | 8 | 2015 | 34134 | 0.060 |
Why?
|
| Hospital Mortality | 1 | 2011 | 1016 | 0.060 |
Why?
|
| Equipment Design | 2 | 2013 | 609 | 0.060 |
Why?
|
| Reproducibility of Results | 1 | 2012 | 2871 | 0.060 |
Why?
|
| Ketolides | 1 | 2005 | 4 | 0.060 |
Why?
|
| Morbidity | 2 | 2006 | 243 | 0.060 |
Why?
|
| Texas | 1 | 2014 | 3586 | 0.060 |
Why?
|
| Nevirapine | 2 | 2016 | 15 | 0.060 |
Why?
|
| Epidemiologic Studies | 2 | 2002 | 43 | 0.060 |
Why?
|
| Abdominal Abscess | 1 | 2005 | 24 | 0.060 |
Why?
|
| Sulfonamides | 1 | 2007 | 261 | 0.060 |
Why?
|
| Cellulitis | 2 | 2007 | 64 | 0.060 |
Why?
|
| Pneumonia, Viral | 1 | 1990 | 373 | 0.060 |
Why?
|
| Age Distribution | 3 | 2007 | 411 | 0.060 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 2 | 2013 | 42 | 0.060 |
Why?
|
| Age Factors | 4 | 2016 | 2812 | 0.060 |
Why?
|
| Water Microbiology | 1 | 2004 | 24 | 0.060 |
Why?
|
| Confidence Intervals | 3 | 2007 | 279 | 0.060 |
Why?
|
| Blood-Borne Pathogens | 1 | 2004 | 3 | 0.060 |
Why?
|
| Biomarkers | 1 | 2013 | 2972 | 0.060 |
Why?
|
| Aged, 80 and over | 2 | 2011 | 6440 | 0.060 |
Why?
|
| Public Health Practice | 1 | 2004 | 21 | 0.060 |
Why?
|
| Catheters, Indwelling | 1 | 2005 | 155 | 0.060 |
Why?
|
| Risk Assessment | 3 | 2016 | 3366 | 0.060 |
Why?
|
| Disease Outbreaks | 2 | 2004 | 321 | 0.060 |
Why?
|
| Blotting, Southern | 1 | 2003 | 215 | 0.050 |
Why?
|
| Peritoneal Dialysis | 1 | 2005 | 119 | 0.050 |
Why?
|
| Infant, Low Birth Weight | 1 | 2004 | 168 | 0.050 |
Why?
|
| Endocarditis, Bacterial | 1 | 2004 | 132 | 0.050 |
Why?
|
| Socioeconomic Factors | 2 | 2016 | 870 | 0.050 |
Why?
|
| Survival Rate | 2 | 2007 | 2018 | 0.050 |
Why?
|
| Campylobacter | 1 | 2002 | 25 | 0.050 |
Why?
|
| Campylobacter Infections | 1 | 2002 | 34 | 0.050 |
Why?
|
| Listeria monocytogenes | 1 | 2002 | 29 | 0.050 |
Why?
|
| Vaccination | 2 | 2004 | 953 | 0.050 |
Why?
|
| Silver Sulfadiazine | 1 | 2002 | 9 | 0.050 |
Why?
|
| Sex Distribution | 2 | 2007 | 295 | 0.050 |
Why?
|
| Ethiopia | 2 | 2014 | 21 | 0.050 |
Why?
|
| Minocycline | 1 | 2002 | 36 | 0.050 |
Why?
|
| Chlorhexidine | 1 | 2002 | 45 | 0.050 |
Why?
|
| Bacterial Proteins | 2 | 2006 | 884 | 0.050 |
Why?
|
| Virulence | 1 | 2002 | 262 | 0.050 |
Why?
|
| Chickens | 1 | 2002 | 638 | 0.050 |
Why?
|
| Pertussis Vaccine | 2 | 2004 | 23 | 0.050 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2002 | 70 | 0.050 |
Why?
|
| Aged | 4 | 2011 | 19383 | 0.050 |
Why?
|
| Rifampin | 1 | 2002 | 127 | 0.050 |
Why?
|
| Sequence Analysis, DNA | 2 | 2006 | 1764 | 0.050 |
Why?
|
| Facial Dermatoses | 1 | 2000 | 8 | 0.050 |
Why?
|
| Mastoiditis | 1 | 2000 | 31 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2001 | 339 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2016 | 3257 | 0.040 |
Why?
|
| Combined Modality Therapy | 2 | 2015 | 1244 | 0.040 |
Why?
|
| Secondary Prevention | 1 | 2001 | 214 | 0.040 |
Why?
|
| Awards and Prizes | 1 | 2020 | 64 | 0.040 |
Why?
|
| HIV-1 | 2 | 2016 | 463 | 0.040 |
Why?
|
| Lymphadenopathy | 1 | 2019 | 29 | 0.040 |
Why?
|
| Genetic Variation | 2 | 2003 | 1491 | 0.040 |
Why?
|
| Respiration, Artificial | 1 | 2002 | 459 | 0.040 |
Why?
|
| Enzyme Inhibitors | 1 | 2002 | 579 | 0.040 |
Why?
|
| Decision Making | 1 | 2004 | 654 | 0.040 |
Why?
|
| Endemic Diseases | 1 | 2018 | 57 | 0.040 |
Why?
|
| Housing | 1 | 1999 | 59 | 0.040 |
Why?
|
| Sudden Infant Death | 1 | 1998 | 33 | 0.040 |
Why?
|
| Francisella tularensis | 1 | 1998 | 15 | 0.040 |
Why?
|
| Virus Activation | 1 | 2018 | 87 | 0.040 |
Why?
|
| Arthritis | 1 | 1998 | 81 | 0.040 |
Why?
|
| Bronchoalveolar Lavage | 1 | 1998 | 24 | 0.040 |
Why?
|
| Coloring Agents | 1 | 1998 | 78 | 0.040 |
Why?
|
| Anemia | 2 | 2013 | 341 | 0.040 |
Why?
|
| Managed Care Programs | 1 | 1998 | 61 | 0.040 |
Why?
|
| Cost Savings | 1 | 1998 | 72 | 0.040 |
Why?
|
| Ehrlichia | 1 | 1997 | 2 | 0.040 |
Why?
|
| Respiratory Syncytial Viruses | 1 | 1998 | 145 | 0.040 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 1998 | 151 | 0.040 |
Why?
|
| Handwriting | 1 | 1997 | 8 | 0.040 |
Why?
|
| Respiratory Sounds | 1 | 1998 | 69 | 0.040 |
Why?
|
| Developed Countries | 1 | 2017 | 36 | 0.040 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2001 | 477 | 0.040 |
Why?
|
| Bronchiolitis | 1 | 1998 | 119 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2002 | 1086 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 1997 | 254 | 0.030 |
Why?
|
| Dexamethasone | 1 | 1998 | 276 | 0.030 |
Why?
|
| Scholarly Communication | 1 | 2017 | 7 | 0.030 |
Why?
|
| Bronchoscopy | 1 | 1998 | 153 | 0.030 |
Why?
|
| Egg Yolk | 1 | 1996 | 4 | 0.030 |
Why?
|
| Income | 1 | 2017 | 133 | 0.030 |
Why?
|
| Egg White | 1 | 1996 | 10 | 0.030 |
Why?
|
| Virus Diseases | 1 | 1999 | 279 | 0.030 |
Why?
|
| Disease Reservoirs | 1 | 1996 | 35 | 0.030 |
Why?
|
| Muscle Weakness | 1 | 1997 | 84 | 0.030 |
Why?
|
| Administration, Topical | 1 | 2016 | 141 | 0.030 |
Why?
|
| Knowledge | 1 | 2016 | 46 | 0.030 |
Why?
|
| Haemophilus Vaccines | 1 | 1996 | 30 | 0.030 |
Why?
|
| Patient Education as Topic | 1 | 1999 | 443 | 0.030 |
Why?
|
| Psychomotor Performance | 1 | 1997 | 182 | 0.030 |
Why?
|
| Physical Examination | 1 | 1997 | 165 | 0.030 |
Why?
|
| Accreditation | 1 | 2016 | 83 | 0.030 |
Why?
|
| Transportation | 1 | 2016 | 26 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 1998 | 1014 | 0.030 |
Why?
|
| Telephone | 1 | 1996 | 110 | 0.030 |
Why?
|
| United States Food and Drug Administration | 1 | 2016 | 150 | 0.030 |
Why?
|
| Osteomyelitis | 1 | 1998 | 205 | 0.030 |
Why?
|
| Religion | 1 | 2016 | 48 | 0.030 |
Why?
|
| Logic | 1 | 2015 | 9 | 0.030 |
Why?
|
| Oral Hygiene | 1 | 2015 | 9 | 0.030 |
Why?
|
| Bleomycin | 1 | 2016 | 150 | 0.030 |
Why?
|
| Zidovudine | 1 | 1995 | 22 | 0.030 |
Why?
|
| Infant, Premature, Diseases | 1 | 1998 | 239 | 0.030 |
Why?
|
| Cultural Characteristics | 1 | 2015 | 40 | 0.030 |
Why?
|
| Social Stigma | 1 | 2016 | 73 | 0.030 |
Why?
|
| Risk | 1 | 2017 | 748 | 0.030 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 1 | 2015 | 20 | 0.030 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 1998 | 203 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 1998 | 511 | 0.030 |
Why?
|
| Remission Induction | 1 | 2016 | 301 | 0.030 |
Why?
|
| Efficiency | 1 | 2015 | 61 | 0.030 |
Why?
|
| Measles | 1 | 1995 | 32 | 0.030 |
Why?
|
| Vincristine | 1 | 2016 | 196 | 0.030 |
Why?
|
| Poultry Products | 1 | 1995 | 2 | 0.030 |
Why?
|
| Career Choice | 1 | 2016 | 143 | 0.030 |
Why?
|
| Models, Educational | 1 | 2015 | 71 | 0.030 |
Why?
|
| Adhesins, Bacterial | 1 | 2015 | 75 | 0.030 |
Why?
|
| Rheumatic Heart Disease | 1 | 2015 | 37 | 0.030 |
Why?
|
| Disease Notification | 1 | 1995 | 8 | 0.030 |
Why?
|
| Sexually Transmitted Diseases, Bacterial | 1 | 1994 | 3 | 0.030 |
Why?
|
| Sexually Transmitted Diseases, Viral | 1 | 1994 | 4 | 0.030 |
Why?
|
| Length of Stay | 2 | 1998 | 1306 | 0.030 |
Why?
|
| Truth Disclosure | 1 | 2016 | 103 | 0.030 |
Why?
|
| Monocytes | 1 | 1997 | 352 | 0.030 |
Why?
|
| DNA, Bacterial | 2 | 2007 | 475 | 0.030 |
Why?
|
| Vaccines, Synthetic | 1 | 1996 | 317 | 0.030 |
Why?
|
| Immunization | 1 | 1996 | 307 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 1995 | 356 | 0.030 |
Why?
|
| Coagulase | 1 | 1994 | 24 | 0.030 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2001 | 625 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 1996 | 299 | 0.030 |
Why?
|
| Complement C3 | 1 | 1994 | 47 | 0.030 |
Why?
|
| Vancomycin | 1 | 1996 | 218 | 0.030 |
Why?
|
| Staphylococcus | 1 | 1994 | 70 | 0.030 |
Why?
|
| Tobacco Smoke Pollution | 1 | 1995 | 76 | 0.030 |
Why?
|
| Bacteriological Techniques | 1 | 1994 | 87 | 0.030 |
Why?
|
| Quality Improvement | 1 | 2020 | 638 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2017 | 1217 | 0.030 |
Why?
|
| Benzoxazines | 1 | 2013 | 24 | 0.030 |
Why?
|
| Alkynes | 1 | 2013 | 26 | 0.030 |
Why?
|
| Catheter-Related Infections | 1 | 2015 | 131 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1997 | 1688 | 0.030 |
Why?
|
| Neuropsychological Tests | 1 | 1997 | 927 | 0.030 |
Why?
|
| Streptococcus agalactiae | 1 | 1994 | 105 | 0.030 |
Why?
|
| Cyclopropanes | 1 | 2013 | 68 | 0.030 |
Why?
|
| Prosthesis-Related Infections | 1 | 2015 | 177 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 1998 | 1096 | 0.030 |
Why?
|
| Pregnancy | 3 | 2012 | 7238 | 0.030 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2013 | 19 | 0.030 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 1 | 1993 | 68 | 0.030 |
Why?
|
| Logistic Models | 2 | 2012 | 1801 | 0.030 |
Why?
|
| Anti-Infective Agents | 1 | 1995 | 266 | 0.030 |
Why?
|
| Emotions | 1 | 2015 | 364 | 0.030 |
Why?
|
| Community Networks | 1 | 2012 | 33 | 0.020 |
Why?
|
| Mouth Neoplasms | 1 | 2013 | 83 | 0.020 |
Why?
|
| Heart Valve Prosthesis | 1 | 2015 | 294 | 0.020 |
Why?
|
| Antibodies, Viral | 1 | 1998 | 1146 | 0.020 |
Why?
|
| Disease Management | 1 | 2016 | 522 | 0.020 |
Why?
|
| Patient Safety | 1 | 2016 | 399 | 0.020 |
Why?
|
| Food, Formulated | 1 | 2012 | 52 | 0.020 |
Why?
|
| Diagnostic Tests, Routine | 1 | 1993 | 117 | 0.020 |
Why?
|
| Dysgammaglobulinemia | 1 | 1991 | 3 | 0.020 |
Why?
|
| Community Health Workers | 1 | 2012 | 64 | 0.020 |
Why?
|
| IgG Deficiency | 1 | 1991 | 2 | 0.020 |
Why?
|
| Receptors, Fc | 1 | 1991 | 28 | 0.020 |
Why?
|
| Anemia, Sickle Cell | 1 | 1995 | 335 | 0.020 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 1991 | 26 | 0.020 |
Why?
|
| Complement System Proteins | 1 | 1991 | 58 | 0.020 |
Why?
|
| Patient Care Team | 1 | 2015 | 546 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 1994 | 771 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 2013 | 226 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 2013 | 376 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 2 | 1996 | 1266 | 0.020 |
Why?
|
| Esophageal Diseases | 1 | 2011 | 35 | 0.020 |
Why?
|
| Immunoglobulins | 1 | 1991 | 170 | 0.020 |
Why?
|
| Cell Separation | 1 | 1991 | 230 | 0.020 |
Why?
|
| Meningitis | 1 | 2011 | 98 | 0.020 |
Why?
|
| Lung | 1 | 1998 | 1485 | 0.020 |
Why?
|
| Cefuroxime | 2 | 2001 | 15 | 0.020 |
Why?
|
| Nutritional Status | 1 | 2012 | 309 | 0.020 |
Why?
|
| Child Mortality | 1 | 2010 | 22 | 0.020 |
Why?
|
| Antiviral Agents | 1 | 1995 | 746 | 0.020 |
Why?
|
| Diagnosis, Differential | 2 | 1998 | 1883 | 0.020 |
Why?
|
| Candidiasis | 1 | 2011 | 129 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 1991 | 969 | 0.020 |
Why?
|
| Pleural Effusion | 2 | 2002 | 101 | 0.020 |
Why?
|
| Health Services Research | 1 | 2011 | 187 | 0.020 |
Why?
|
| Prenatal Care | 1 | 2012 | 347 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 1991 | 804 | 0.020 |
Why?
|
| Escherichia coli | 1 | 1994 | 982 | 0.020 |
Why?
|
| Odds Ratio | 2 | 2007 | 1245 | 0.020 |
Why?
|
| Prednisone | 1 | 2009 | 274 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2012 | 1330 | 0.020 |
Why?
|
| Cause of Death | 1 | 2010 | 466 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2009 | 281 | 0.020 |
Why?
|
| Blood Chemical Analysis | 1 | 2007 | 79 | 0.020 |
Why?
|
| Deoxyribonucleases, Type II Site-Specific | 1 | 2006 | 49 | 0.020 |
Why?
|
| Infant, Premature | 1 | 1991 | 812 | 0.020 |
Why?
|
| Skin Neoplasms | 1 | 2013 | 801 | 0.020 |
Why?
|
| Methyltransferases | 1 | 2006 | 71 | 0.020 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 2006 | 369 | 0.020 |
Why?
|
| Hearing Loss | 1 | 2006 | 132 | 0.020 |
Why?
|
| Debridement | 1 | 2005 | 88 | 0.010 |
Why?
|
| Patient Isolation | 1 | 2004 | 14 | 0.010 |
Why?
|
| Heart Defects, Congenital | 1 | 2015 | 1813 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 2006 | 1082 | 0.010 |
Why?
|
| Device Removal | 1 | 2005 | 222 | 0.010 |
Why?
|
| Lung Abscess | 1 | 2002 | 14 | 0.010 |
Why?
|
| Meat Products | 1 | 2002 | 5 | 0.010 |
Why?
|
| Interviews as Topic | 1 | 2004 | 373 | 0.010 |
Why?
|
| Food Contamination | 1 | 2002 | 23 | 0.010 |
Why?
|
| Empyema | 1 | 2002 | 23 | 0.010 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2003 | 134 | 0.010 |
Why?
|
| Age of Onset | 1 | 2003 | 582 | 0.010 |
Why?
|
| Bacterial Typing Techniques | 1 | 2002 | 103 | 0.010 |
Why?
|
| Acute Disease | 1 | 2005 | 1098 | 0.010 |
Why?
|
| Ribotyping | 1 | 2002 | 50 | 0.010 |
Why?
|
| Necrosis | 1 | 2002 | 205 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2011 | 4725 | 0.010 |
Why?
|
| Child, Hospitalized | 1 | 2002 | 74 | 0.010 |
Why?
|
| Serologic Tests | 1 | 2002 | 118 | 0.010 |
Why?
|
| Leukocytosis | 1 | 2000 | 45 | 0.010 |
Why?
|
| Mortality | 1 | 2002 | 229 | 0.010 |
Why?
|
| Phylogeny | 1 | 2002 | 696 | 0.010 |
Why?
|
| Empyema, Pleural | 1 | 1998 | 23 | 0.010 |
Why?
|
| Nasal Lavage Fluid | 1 | 1998 | 14 | 0.010 |
Why?
|
| Benzophenoneidum | 1 | 1998 | 1 | 0.010 |
Why?
|
| Rhodamines | 1 | 1998 | 22 | 0.010 |
Why?
|
| Nocardia Infections | 1 | 1998 | 15 | 0.010 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 1998 | 105 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2006 | 1522 | 0.010 |
Why?
|
| Deafness | 1 | 1998 | 82 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1998 | 816 | 0.010 |
Why?
|
| Radiography | 1 | 1998 | 823 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1996 | 257 | 0.010 |
Why?
|
| Disease Transmission, Infectious | 1 | 1995 | 86 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 1994 | 247 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 1998 | 2127 | 0.010 |
Why?
|
| Rural Population | 1 | 1995 | 256 | 0.010 |
Why?
|
| Phenotype | 1 | 2002 | 4253 | 0.010 |
Why?
|